

Asia Pacific Pharmaceuticals & Drug Delivery Congress

Dr. Tarek Motawi

Welcome Message:

[Conference Series](#) take the pleasure to proudly present “Asia Pacific Pharmaceuticals & Drug Delivery Congress” during November 09-10, 2020 in Tokyo, [Japan](#) with the theme “Creating breakthrough medicines to improve the quality of life”.

Importance and Scope:

The Pharmaceutical industry has an important role in designing and developing drugs, vaccines. It plays a significant role to treat diseases and more importantly to improve the quality of life. The Pharmaceutical industry is mostly engaged in the technological advancement through scientific research so that it can encounter the demand of the large population in the healthcare sector. The widespread presence of chronic diseases and the growing demand of medication has become a driving force for the pharmaceutical industry to grow rapidly. The discovery of pathogens and development of drugs to treat the patients also contribute to the increasing growth of pharmaceutical industry. The pharmaceutical manufacturing industry is classified into tablets, capsules, powders, emulsions and many others. There is a rise in demand of oral based medicine due to their ease in availability, dosage and affordability.

Growth of Pharmaceutical Industry in recent years:

According to a recent market research on Pharmaceutical Market by the Business research Company the pharmaceutical industry market was worth \$934.8 billion in 2017 and is expected to reach \$1170 billion in 2021 growing at the rate of 5.8%. Globally, America is the largest Pharmaceutical manufactures, and is expected to grow to \$320 billion by 2020. The Asia Pacific region is also expected to grow because of its rapidly growing Countries like China, which is soon going to be the World’s second largest Pharmaceutical market. Countries such as Japan, India, and South Korea are expecting huge sales as a result of adaptation of healthy lifestyle, expanding medical tourism, low labor cost.


Part of the explanation for the relatively slow current growth of the pharma market is that the launch of major new products has slowed and that companies are restricting their R&D investment. For example, despite the huge potential for any effective and safe new drug for treating Alzheimer’s disease, Pfizer has ended its Alzheimer’s research program while AstraZeneca and GSK have cut back. High failure rates, the \$2 billion average cost of developing a new drug, and falling returns on investment – down from 10.1% a year in 2010 to 3.2% in 2017 for the big pharma

Companies, according to Deloitte’s – are restraining the launch of high-priced new breakthrough drugs such as those that boosted the market in earlier years.

Most pharmaceutical industry growth now is coming instead from the increased size of the global aging population, which boosts demand for long-term treatments for chronic diseases, and better access to healthcare in emerging economies.

The largest pharma market globally is for musculoskeletal drugs. These are treatments for diseases such as rheumatoid- and osteo- arthritis, osteoporosis, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Major drugs in this segment include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The segment accounted for 14% of the global total in 2017. Cardiovascular, oncology and anti-infective drugs are the second third and fourth largest markets.

Drugs for treating metabolic disorders such as diabetes and diseases of the thyroid and pituitary glands will be the fastest-growing segment of the global pharma market to 2021. This segment will grow at 9% a year going forward, following recent growth of 11.6%, but it will remain in fifth place for market size.



Pharmaceutical drugs are subject to a large number of laws and regulations that deal with patenting, testing, safety, efficacy and marketing and affect the size and growth rates of the market. Together with the high R&D costs involved in creating new drug solutions, these can act as barriers to entry for small companies. However, pharmaceutical companies produce both generic and branded drugs. Generics, which are copies of patent-expired drugs, are opportunities for smaller entrants. They are taking an increasing share of the market, particularly in developing economies, where governments are encouraging their production in order to make

lower-price treatments more widely available.

Together the top ten pharmaceutical companies account for 30% of global sales, making the market moderately fragmented. Within individual segments, however, the share of these pharmaceutical companies varies: Hoffman-La Roche is by some way the leading pharmaceutical company in the large oncology drugs market, but Sanofi leads in the cardiovascular and metabolic disorders segments.

In markets where biologics have penetrated, the leading players are not in the top ten pharma manufacturers: Biogen, for instance, leads in the central nervous system segment, while Bristol-Myers Squibb and Eli Lilly have significant shares in oncology.

Deal activity in the healthcare industry has surged in recent years. Most mergers and acquisitions are aimed at boosting product portfolios and expanding the market reach of products and services. For example, in August 2014 Merck acquired a clinical-stage pharmaceutical company, Idenix Pharmaceuticals Inc., for nearly \$4 billion. Through this acquisition Merck strengthened its product portfolio by adding Idenix's potential hepatitis drugs.

Top Pharmaceutical association in the world:

- International Pharmaceutical Federation (FIP)
- International Pharmaceutical Students' Federation (IPSF)
- American Association of Colleges of Pharmacy (AACP)
- American Pharmacists Association (APhA)
- American Society for Pharmacy Law
- American Society of Consultant Pharmacists (ASCP)
- American Society of Health-System Pharmacists (ASHP)
- Professional Compounding Centers of America

- American College of Clinical Pharmacy (ACCP)
- College of Psychiatric and Neurologic Pharmacists (CPNP)
- European Association of Employed Community Pharmacists in Europe (EPHEU)
- Pharmaceutical Group of the European Union (PGEU)
- Australian College of Pharmacy
- Pharmaceutical Society of Australia
- The Pharmacy Guild of Australia
- The Society of Hospital Pharmacists of Australia

Top Pharmaceutical Industry in the world:

- Johnson & Johnson
- Novartis
- Roche
- Pfizer
- Sanofi
- Merck
- GSK (GlaxoSmithKline)
- AstraZeneca
- Bayer
- Gilead Sciences

Pharmaceutical drugs global market, global pharmaceutical drugs market by therapeutic area segments and subsegments; pharmaceutical drugs market by region and country and by therapeutic area segments; branded versus generic drugs markets by country; competitor drug sales and market shares by therapeutic area; global healthcare market historic and forecast size and growth; healthcare market regional and country size and growth; healthcare market competitive landscape.